Evidence map›Paper›PMID 41155957›Full record

ReviewPharmaceutics2025

Advances in Nasal Biopharmaceutics to Support Product Development and Therapeutic Needs.

Ben Forbes, Lucy Goodacre, Alison B Lansley, Andrew R Martin, Helen Palmer, Claire Patterson, Chris Roe, Regina Scherließ

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ben ForbesInstitute of Pharmaceutical Science, King's College London, London SE1 9NH, UK.ORCID 0000-0001-8193-6107
Lucy GoodacreInstitute of Pharmaceutical Science, King's College London, London SE1 9NH, UK.ORCID 0009-0004-4853-4842
Alison B LansleySchool of Applied Sciences, University of Brighton, Brighton BN2 4GJ, UK.
Andrew R MartinMechanical Engineering and Biomedical Engineering, University of Alberta, Edmonton, AB T6G 1H9, Canada.ORCID 0009-0000-6793-9168
Helen PalmerLabcorp, Early Development Laboratories Ltd., Huntingdon PE28 4HS, UK.
Claire PattersonSeda Pharmaceutical Development Services, Stockport SK8 3GX, UK.ORCID 0000-0001-6223-9525
Chris RoeQuotient Sciences, Nottingham NG11 6JS, UK.
Regina ScherließDepartment of Pharmaceutics and Biopharmaceutics, Kiel University, 24118 Kiel, Germany.ORCID 0000-0001-8685-5672

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cell and mucus modelsgamma scintigraphynasal depositionnasal drug productsPBBMpreclinical development

Identifiers

PMID41155957
PMCPMC12566803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.